UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

European journal of cancer (1990), 2015-09, Vol.51, p.S446-S446

2015

Volltextzugriff (PDF)

217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma

European journal of cancer (1990), 2014-11, Vol.50, p.73-74

2014

Volltextzugriff (PDF)

8513 POSTER DISCUSSION A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Head and Neck Cancer – Representative of Head and Neck Cancer Study Group of Taiwan Cooperative Oncology Group

European journal of cancer (1990), 2011, Vol.47, p.S547-S548

2011

Volltextzugriff (PDF)

408P Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment

Annals of oncology, 2023-11, Vol.34, p.S1624

2023

Volltextzugriff (PDF)

412P Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma

Annals of oncology, 2023-11, Vol.34, p.S1625

2023

Volltextzugriff (PDF)

6585 POSTER Phase II Study of Low-dose Everolimus Plus Weekly Cisplatin and 24-hour Infusion of High-dose 5-fluorouracil and Leucovorin for First-line Treatment of Metastatic or Recurrent Gastric Cancers

European journal of cancer (1990), 2011, Vol.47, p.S467-S467

2011

Volltextzugriff (PDF)

161P Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis

Annals of oncology, 2020-11, Vol.31, p.S1302-S1302

2020

Volltextzugriff (PDF)

78P First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors

Annals of oncology, 2023-11, Vol.34, p.S1497

2023

Volltextzugriff (PDF)

401P Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

Annals of oncology, 2024-06, Vol.35, p.S163-S164

2024

Volltextzugriff (PDF)

138MO Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis

Annals of oncology, 2023-11, Vol.34, p.S1526

2023

Volltextzugriff (PDF)

Quantitative EPMA and Compositional Mapping of Nakhlite Northwest Africa 14369

Microscopy and microanalysis, 2022-08, Vol.28 (S1), p.614-616

2022

Volltextzugriff (PDF)

163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study

Annals of oncology, 2021-12, Vol.32, p.S1452

2021

Volltextzugriff (PDF)

117TiP BGB-HNSCC-201 (NCT05909904): Phase II, open-label, multi-arm, global study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Immuno-oncology technology, 2023-12, Vol.20, p.100659, Article 100659

2023

Volltextzugriff (PDF)

Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Annals of oncology, 2019-10, Vol.30, p.v289-v290

2019

Volltextzugriff (PDF)

753P - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Annals of oncology, 2019-10, Vol.30, p.v289-v290

2019

Volltextzugriff (PDF)

342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

Annals of oncology, 2015-12, Vol.26, p.ix93-ix93

2015

Volltextzugriff (PDF)

A rare and under-recognized pathogen in peritoneal dialysis peritonitis: Corynebacterium jeikeium

Peritoneal dialysis international, 2013-09, Vol.33 (5), p.580-581

2013

Volltextzugriff (PDF)

Laying traits and underlying transcripts, expressed in the hypothalamus and pituitary gland, that were associated with egg production variability in chickens

Theriogenology, 2007-12, Vol.68 (9), p.1305-1315

2007

Volltextzugriff (PDF)

Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study

Annals of oncology, 2014-09, Vol.25, p.v1

2014

Volltextzugriff (PDF)

Characteristics of air pressure fluctuations in high-rise drainage stacks

Building and environment, 2010-03, Vol.45 (3), p.684-690

2010

Volltextzugriff (PDF)

Prolonged chlorambucil therapy for idiopathic membranous nephropathy may induce myelodysplastic syndrome and acute leukemia: report of a case

Clinical nephrology, 2004-12, Vol.62 (6), p.477

2004

Volltextzugriff (PDF)

LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY

Annals of oncology, 2014-09, Vol.25 (suppl_4)

2014

Volltextzugriff (PDF)

Fabrication, superconducting Tc and charge transfer of VNx NbNx and TaNx foils

Physics letters. A, 1996-07, Vol.217 (2-3), p.167-175

1996

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(86)
Mit Volltextzugriff
(101)

Publikationsform

Sprache

Englisch
(103)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(31)
Humans
(21)
Technology
(15)
Physical Sciences
(14)
Biological And Medical Sciences
(13)
Engineering
(12)
Female
(12)
Animals
(9)
Fundamental And Applied Biological Sciences. Psychology
(8)
Male
(8)
Engineering, Electrical & Electronic
(6)
Biochemistry & Molecular Biology
(5)
Chemistry
(5)
General & Internal Medicine
(5)
Hematology, Oncology And Palliative Medicine
(5)
Mechanics
(5)
Medical Sciences
(5)
Surgery
(5)
Adult
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma

408P Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment

412P Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma

6585 POSTER Phase II Study of Low-dose Everolimus Plus Weekly Cisplatin and 24-hour Infusion of High-dose 5-fluorouracil and Leucovorin for First-line Treatment of Metastatic or Recurrent Gastric Cancers

161P Adjuvant tegafur/gimeracil/oteracil (S-1) versus platinum-based chemotherapies for resectable gastric cancer: Real-world experience and a propensity score matching analysis

78P First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors

401P Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study

138MO Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis

Quantitative EPMA and Compositional Mapping of Nakhlite Northwest Africa 14369

163P Health-related quality of life (HRQoL) with pembrolizumab (pembro) vs chemotherapy (chemo) in platinum-pretreated recurrent or metastatic (R/M) nasopharyngeal cancer (NPC): Phase III KEYNOTE-122 study

117TiP BGB-HNSCC-201 (NCT05909904): Phase II, open-label, multi-arm, global study of tislelizumab (TIS) + investigational agents as first-line (1L) treatment in patients (Pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

1212P - Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

753P - Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

A rare and under-recognized pathogen in peritoneal dialysis peritonitis: Corynebacterium jeikeium

Laying traits and underlying transcripts, expressed in the hypothalamus and pituitary gland, that were associated with egg production variability in chickens

Ramucirumab (Ram) As Second-Line Treatment in Patients (Pts) with Advanced Hepatocellular Carcinoma (Hcc) Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III Reach Study

Characteristics of air pressure fluctuations in high-rise drainage stacks

Prolonged chlorambucil therapy for idiopathic membranous nephropathy may induce myelodysplastic syndrome and acute leukemia: report of a case

LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY

Fabrication, superconducting Tc and charge transfer of VNx NbNx and TaNx foils

Suchergebnisse filtern